NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
Talent Pool executive appointments and promotions in the healthcare industry
Former Amgen VP Joins Vertex
Vertex Pharmaceuticals has appointed Stuart Arbuckle as executive VP and chief commercial officer. Mr. Arbuckle most recently served as Amgen’s VP and regional general manager, leading efforts to expand the biotech company’s presence in Japan and emerging markets in Asia, the Middle East, and Africa.
Dr. Jonathan ISAACSOHN
Teva Appoints Medical Chief
Israeli pharmaceutical company Teva Pharmaceutical Industries has appointed Jonathan Isaacsohn, MBChB, chief medical officer. Dr. Isaacsohn provides medical perspective and input to Teva’s generic R&D activities, branded development strategy, and business development efforts. He is also responsible for Teva’s respiratory R&D, pharmacovigilance group global health initiatives, and health economics. Dr. Isaacsohn was most recently executive VP and head of medical and regulatory affairs at Medpace. He received an MBChB from the University of Cape Town Medical School in South Africa.
Dr. Glenn NORONHA
Sucampo Appoints R&D VP
Sucampo Pharmaceuticals, a global pharmaceutical company focused on discovery, development, and commercialization of proprietary drugs based on prostones, has named Glenn Noronha, Ph.D., VP of research and development for Sucampo Pharma Americas.
Dr. Noronha was chief scientific officer for JW Theriac. He received a Ph.D. in organometallic chemistry from Loyola University Chicago.
VaxInnate Adds VPs
VaxInnate, a biotechnology firm pioneering breakthrough technology for the development of novel vaccines, has expanded its executive management team.
Katalin Abraham has joined VaxInnate as VP of regulatory affairs. Ms. Abraham was most recently director of regulatory affairs at GlaxoSmithKline.
VaxInnate has appointed Christine Mayer VP of business development, where she is using her experience in collaborations and partnerships to help VaxInnate achieve its strategic vision. Ms. Mayer was previously senior VP of business development at Biovail Pharmaceuticals. She holds a master’s degree from Rutgers University.
Dr. Ernest BUSH
Dr. Elliot GOLDSTEIN
Dart Therapeutics Unveils Executive Team
Dart Therapeutics, a new-model biotechnology firm focused on developing therapies for Duchenne Muscular Dystrophy (DMD), has announced the appointment of its executive team.
Ernest Bush, Ph.D., has joined Dart as chief scientific officer. Dr. Bush has more than 30 years of experience in biomedical R&D for major pharmaceutical companies, including Roche, where he was responsible for the preclinical safety department.
Dart has named Dr. Elliot Goldstein chief medical officer. Dr. Goldstein’s more than 25 years of executive-level pharmaceutical and biotechnology expertise include senior management roles at Sandoz, Novartis, SmithKline Beecham, and Maxygen.
Dart Co-Founder and Executive Chairman Eugene Williams has transitioned to a full-time role as CEO. Mr. Williams has more than 25 years of experience as a senior manager at major biotech firms, including Genzyme, and brings to Dart experience and accomplishment in pediatric rare diseases, global development, business development, portfolio management, and entrepreneurship.
Dr. Robert CLARKE
Pulmatrix Promotes Scientific Chief to CEO
Pulmatrix, a clinical-stage biotechnology company creating novel inhaled therapeutics, has promoted Robert Clarke, Ph.D., to CEO, succeeding Robert Connelly, who left the company to lead a startup. Dr. Clarke was previously chief scientific officer and VP of research and development. He received a Ph.D. in physiology from Johns Hopkins University.
Amgen Selects Corporate Affairs VP
Amgen has appointed Ray Jordan senior VP, corporate affairs, responsible for strategic communications across the global biotech company, including internal and external communications, issues management, and philanthropy. Mr. Jordan previously served as communications leader at Johnson & Johnson.
Dr. Matthew PLUNKETT
Cell Therapeutics Appoints Corporate Development VP
Cell Therapeutics (CTI), a biopharma company focused on translating science into novel cancer therapies, has named Matthew Plunkett, Ph.D., executive VP, corporate development. Dr. Plunkett leads CTI’s partnering strategy, including development collaborations, licensing agreements, and strategic alliances.
Most recently, Dr. Plunkett was chief financial officer for the California Institute for Regenerative Medicine. Dr. Plunkett received a doctorate in organic chemistry from the University of California, Berkeley.
Immunovative Names Chief Executive
Immunovative Inc., the U.S.-based commercial arm of private Israeli biopharmaceutical company Immunovative Therapies Ltd., has named Seth Shaw to succeed Antonio Treminio as chairman and CEO. Mr. Shaw has experience building companies and securing financing from a broad range of both domestic and international institutional investors.
Dr. Harold SHLEVIN
Galectin Therapeutics Selects Operating Chief
Galectin Therapeutics, a developer of therapeutics that target galectin proteins to treat fibrosis and cancer, has appointed Harold Shlevin, Ph.D., chief operating officer. An executive with 25 years of senior management experience in the development and commercialization of pharmaceuticals, diagnostics, and vaccines, Dr. Shlevin most recently led Georgia Institute of Technology’s Advanced Technology Development Center (ATDC) as principle and manager of bioscience commercialization efforts. He earned an M.S. and a Ph.D. in physiology from the University of Rochester Medical School.
Actinium Pharmaceuticals Strengthens Management Team
Actinium Pharmaceuticals (API), a private biopharmaceutical company that develops innovative targeted radioimmunotherapeutics, has appointed Jack Talley president and CEO as the company prepares to take its stock public.
An industry veteran with more than three decades of experience, Mr. Talley is responsible for guiding two companies through the transition to becoming public reporting entities, Penwest Pharmaceuticals and EpiCept, the latter of which he recently served as president and CEO.
Dr. Patrick VINK
Cubist Taps Former Mylan VP as International Business Manager
Cubist Pharmaceuticals, a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address significant unmet medical needs in the acute care environment, has named Patrick Vink, M.D., senior VP and general manager of its international business. Based in Switzerland, Dr. Vink is responsible for overseeing Cubist’s commercial opportunities across Europe and in select developing markets. Dr. Vink most recently served as Mylan’s senior VP, global head of its hospital business and global head of biologics. He received a doctorate of medicine from the University of Leiden in the Netherlands and an MBA from Erasmus University in Rotterdam, the Netherlands.
Dr. Jeff ENEJOSA
Tobira Therapeutics Completes Senior Management Team
Tobira Therapeutics, a privately held developer of antiretroviral therapies for HIV, has added two executives to its clinical and pharmaceutical sciences functions. Jeff Enejosa, M.D., has joined Tobira as senior director, clinical research. A board-certified internal medicine physician with specialty in HIV medicine, Dr. Enejosa was previously director, clinical research, at Gilead Sciences.
Mark Menning has been named director, pharmaceutical sciences. Mr. Menning most recently served as senior research scientist, formulation and process development, for Gilead Sciences.
Patrick (Pat) GALLAGHER
Kinex Pharmaceuticals Appoints Business Development VP
Kinex Pharmaceuticals, a specialty pharmaceutical company focused on the development and commercialization of next-generation therapies for cancer and immunomodulatory diseases, has appointed Patrick (Pat) Gallagher VP, business development and investor relations. Mr. Gallagher has almost two decades of experience as a capital markets executive, advisor, and investor in both the public and private markets.
Dr. Thomas PITLER
A.P. Pharma Names Business Development VP
A.P. Pharma, a specialty pharmaceutical company developing products using its proprietary Biochronomer polymer-based drug delivery platform, has named Thomas Pitler, Ph.D., VP of business development. Dr. Pitler was previously VP of business development at Chimerix. He received a Ph.D. in physiology from Wake Forest University.
Dr. Hubert CHEN
Aileron Prepares to Advance First Drug Candidate
Aileron Therapeutics has appointed Hubert Chen, M.D., VP of clinical development, endocrine and metabolic disease. The appointment comes as Aileron prepares to initiate clinical development in early 2013 of its first stapled peptide drug candidate, ALRN-5281, a proprietary, long-acting growth-hormone-releasing hormone (GHRH) agonist for treating orphan disorders, including adult growth hormone (GH) deficiency and HIV lipodystrophy, as well as broader patient populations such as GH-deficient abdominal obesity.
Dr. Chen joins Aileron from Regulus Therapeutics, where he served as VP of translational medicine. He holds an M.D. from Columbia University.
Dr. Thomas PARR
Fedora Pharmaceuticals Names Scientific Chief
Fedora Pharmaceuticals has named Thomas Parr, Ph.D., to the newly created position of chief scientific officer. Dr. Parr was most recently chief scientific officer at Targanta Therapeutics. He received a Ph.D. in microbiology and infectious diseases from the University of Calgary.
Fedora Pharmaceuticals is a private biotechnology company developing a portfolio of beta lactamase inhibitors that have the unique ability to resensitize resistant bacteria to currently used beta lactam antibiotics. The company is in the lead optimization stage of preclinical development with multiple beta lactamase inhibitor molecules.
Dr. Rob SARISKY
Forma Therapeutics Selects Former Janssen VP as Business Chief
Forma Therapeutics has named Rob Sarisky, Ph.D., chief business officer. Dr. Sarisky was most recently VP of oncology business development and licensing within Janssen Pharmaceuticals, a Johnson & Johnson company. He received a Ph.D. in genetics from the Pennsylvania State University College of Medicine and an MBA in marketing from Lehigh University.
Forma Therapeutics is building a robust pipeline of cancer therapies in areas such as tumor metabolism, protein-protein interactions, and epigenetics using an approach that targets essential cancer pathways to create transformative small molecule cancer therapies.
Ogilvy CommonHealth Bolsters Interactive Marketing Agency
Ogilvy CommonHealth Worldwide, the health behavior experts of Ogilvy & Mather and a WPP company, has announced additions and promotions to its Ogilvy CommonHealth Interactive Marketing team.
Matt Balogh has been promoted to senior VP, director of technology, from VP, director of technology. Mr. Balogh’s responsibilities include overseeing all of the interactive development and quality assurance teams.
Max Divak has been promoted to interactive development manager, from associate interactive development manager. Mr. Divak’s responsibilities include mentoring the development team, brainstorming and estimating project scopes, and successfully deploying assets for his assigned brands.
Nelson Figueiredo has been elevated to VP, associate director of technology, from associate interactive development manager. His responsibilities include analyzing client business needs and forming solutions and digital strategies for their brands.
Carissa Keppel has advanced to interactive art director, from associate interactive designer, working directly with the group’s creative directors to aid in the design and execution of various interactive projects from conception to completion.
Kathie Marshall has been promoted to senior VP, director of project management, from VP, associate director of project management. Ms. Marshall’s responsibilities include contributing to new business development initiatives and supervising her team of project managers to ensure clients’ needs and deadlines are met in a successful and timely manner.
Ryan Oleson has joined Ogilvy CommonHealth Interactive Marketing as VP, management supervisor, overseeing all interactive client deliverables on his assigned accounts and acting as the main liaison between the agency and its clients. Mr. Oleson was most recently VP, director of marketing, at Digitas Health.
Fred Petito has been appointed senior VP, managing director. Mr. Petito is responsible for developing strategic digital marketing plans, managing client relations, and lending his digital expertise for client engagements to other Ogilvy CommonHealth groups. Mr. Petito was previously group director of digital marketing at G2.
Centron Announces Staff Additions
Full-service medical communications agency Centron, a HealthSTAR Communications company, has added a number of new staff members to its accounts management team.
Florence Baskin has joined Centron as an account group supervisor. Ms. Baskin was previously account supervisor at Draft FCB Healthcare.
David Manevitz has been named a senior account executive. Mr. Manevitz was most recently an account executive with CDM.
Scott Montgomery has been appointed a VP, account supervisor, on Centron’s medical education team. Mr. Montgomery joins Centron from Asante Communications, where he was an account supervisor.
Centron has named Hollister Robinson a VP, account group supervisor, on the medical education team. Ms. Robinson was previously a VP, account supervisor, for CDM.
Lee Williams has joined Centron as an account supervisor, from the same position at LLNS.
Helen Wong has been appointed senior VP, management supervisor. Ms. Wong was most recently senior VP with The Falk Group.
Mary Ellen HACKETT
Accounts Team Promotions at Spectrum
Spectrum, a communications counseling firm specializing in health and science, has made a number of promotions among its accounts staff members.
Liz Bryan, who has been with Spectrum since 2007, has been promoted to account director. Ms. Bryan is responsible for supporting public relations initiatives for several clients and specializing in strategic planning, advocacy relations, securing media placements, and multimedia asset production. She received an M.S. in public relations from the S.I. Newhouse School of Public Communication at Syracuse University.
Lauren Fulk has been appointed account director, managing scientific communications efforts for a consumer products company and leading day-to-day activities for a novel biotech company by supporting digital and traditional media campaigns. Ms. Fulk first joined Spectrum in 2005.
Mary Ellen Hackett has been promoted to VP. Ms. Hackett offers more than 20 years of experience in healthcare communications, as a journalist and as an adviser to health-related organizations and enterprises. She received an M.S. in communications management from the S.I. Newhouse School of Public Communications at Syracuse University.
Megan Lustig has been named account director, supporting public relations activities for several clients and focusing on strategic planning, media relations, and scientific credentialing. Ms. Lustig first joined Spectrum in 2005.
Darby Pearson has been promoted to VP, supervising international and domestic U.S. scientific communications efforts for a major consumer products company. Ms. Pearson also directs the day-to-day activities for GLOBALHealthPR, a worldwide partnership of independent communications agencies dedicated exclusively to healthcare and chaired by Spectrum. She has been with Spectrum since 2007.
Eight-year Spectrum veteran Amanda Sellers has been promoted to senior VP, client service. Ms. Sellers has agency-wide responsibility for ensuring the highest levels of service, as well as overseeing the profitability and growth of current accounts.
MCS Announces Promotion
Global communications agency MCS Healthcare Public Relations has promoted Matt Coppola to account executive, from account representative. Mr. Coppola provides support in the development and execution of various professional and consumer media campaigns for his clients, which include Merck, BD, CSL Behring, Genentech, and MannKind Corporation. In addition, Mr. Coppola is actively involved in the implementation of specialty trade and social media campaigns that enhance clients’ brand recognition and reputation among target audiences.
Havas Worldwide Health Appoints European CEO
Havas Worldwide Health, a health and wellness communications agency, has named Ben Davies CEO of its European division. Mr. Davies succeeds Ed Stapor, who has assumed a new challenge within the network. He joins Havas from PAN Advertising, where he was most recently CEO.
Signature Brand Factory Strengthens its team
Signature Brand Factory has made a number of promotions and additions to its team. Brian Kelley has been promoted to manager of interactive services from interactive designer. Mr. Kelley has been with Signature for almost four years, using his wide range of talents to execute campaigns for entertainment, corporate, healthcare, and consumer projects.
Paul Rodrigues has been promoted to VP of creative services, from associate creative director. With nearly a decade at Signature, Mr. Rodrigues has been crucial in providing the creative oversight of all the agency’s campaigns.
David Schemelia has joined Signature as director of public relations after running his own consulting firm. Before that, Mr. Schemelia spent more than 15 years working in PR and more than 20 years as a journalist.
Navicor Appoints Client Services Director
The Navicor Group, an inVentiv Health company and full-service advertising agency specializing in oncology and immunology brands, has named Greg Niemczyk senior VP, director of client services. Mr. Niemczyk’s responsibilities include overseeing agency teams and provide strategic guidance for several of the agency’s top accounts, as well as developing and leading client service solutions for the entire agency. Before joining Navicor, Mr. Niemczyk served as VP, account director, for AbelsonTaylor.
Huron Strengthens Life Sciences Practice
Huron Consulting Group has appointed Brad Dawson a managing director in its Huron Life Sciences practice. Mr. Dawson will be focused on advising pharmaceutical and medical device companies in the area of research and development process transformation to improve operational efficiencies, address regulatory compliance vulnerabilities, and enhance the overall value of the development pipeline.
Mr. Dawson was previously with Quintiles Consulting, where he served as the principal and practice leader for R&D process optimization.
Kantar Health Announces Promotion
Kantar Health, a healthcare-focused global consultancy and marketing insights company, has promoted Graeme Jacombs to managing director of the Asia Pacific, Middle East, and Africa (APMEA) region, from deputy managing director, APMEA. Mr. Jacombs is responsible for Kantar Health’s regional strategy, local business planning, and client support in Asia, Australia/New Zealand, India, the Middle East, and Africa.
CIS Advances Global Clinical Compliance Solutions
Compliance Implementation Services (CIS) has named Anne McCormick director, clinical consulting and quality assurance. Ms. McCormick leads the strategy and growth of CIS’ clinical business area to effectively help clients analyze business processes, evaluate inspection-readiness, and understand GCP regulatory requirements.
Ms. McCormick was most recently director at Pharmaceutical Excel Consulting. She received an M.A. from California State University, Sacramento.
Dr. Alexandra ADAMS
Dr. Dieter SEITZ-TUTTER
Chiltern Strengthens European Executive Team
Alexandra Adams, Ph.D., has joined global CRO Chiltern International as director, late phase, Europe. Based in the United Kingdom, Dr. Adams leads the global late phase group in Europe, which is focused on implementing tailored solutions for late-phase studies and registries in a cost-effective way.
Dr. Adams has 25 years of experience in both pharma and CRO. She received a Ph.D. in biochemistry/pharmacology from the Cardiothoracic Institute at the University of London.
In other moves, Chiltern has appointed Dieter Seitz-Tutter, Ph.D., VP, global clinical development, Europe. Dr. Seitz-Tutter is based in Munich and is responsible for leading Chiltern’s global clinical development business, comprising clinical operations and project management, across Europe.
Dr. Seitz-Tutter has more than 22 years of experience in the clinical research field for both pharma and CROs, most recently serving as VP, Europe, with a global corporation. He holds a master’s degree and a doctorate in biology from the University of Munich.
Leadership Succession at INC Research
INC Research, a therapeutically focused CRO, has instituted a succession plan that includes a number of additions and promotions among its top executives.
Susan Akers-Smith has been promoted to VP, early phase oncology development, from executive director of clinical development. Ms. Akers-Smith provides global leadership for delivery of advanced clinical development solutions to meet the diverse early phase needs of INC Research’s oncology customers.
Neil Ferguson has joined INC Research as executive VP, business development, with global responsibility for business development, marketing, proposals, and strategic alliance development. Mr. Ferguson previously served as VP and head of commercial sales for North America at Quintiles.
INC has promoted Alistair Macdonald to chief operating officer, from president, clinical development services. Alistair Macdonald has almost 20 years of experience in the CRO industry, including a decade with INC Research.
Alistair Macdonald succeeds Jamie Macdonald, who has been promoted to president and CEO. As CEO of INC Research, Jamie Macdonald succeeds James Ogle, who remains chairman of the company.
AMRI Promotes Business Development Director
Albany Molecular Research (AMRI) has promoted Daniel Conlon to senior director, business development, leading the global contract research and manufacturing organization’s development and manufacturing services sales team for North America. Mr. Conlon’s responsibilities include assisting with the strategic direction for generating sales in the North American territory and the execution of revenue goals for his team. He first joined AMRI in 2010.
Dr. Jim ESINHART
Chiltern Announces CEO Succession
Chiltern International has announced a CEO succession with Glenn Kerkhof stepping down and Jim Esinhart, Ph.D., appointed. After six years in the post, Mr. Kerkhof steps down as CEO and joins Chiltern’s owner Czura Thornton as a partner, as well as the Chiltern’s board of directors.
Mr. Kerkhof has also relocated to his native Australia and leads Czura Thornton’s growth in the Asia Pacific region. Dr. Eisinhart was previously Chiltern’s senior executive VP, global scientific services and has served with the company for six years. He has more than 24 years of industry experience.
RPS Names Information Chief
ReSearch Pharmaceutical Services (RPS), a next-generation CRO that provides comprehensive global Phase I-IV clinical development solutions to the biopharmaceutical and medical device industries, has appointed Stephen Kasay chief information officer. Mr. Kasay has responsibility for the global information technology function of RPS, including IT strategy development and optimization of technology infrastructure, software systems, and enterprise data assets.
Mr. Kasay has more than three decades of healthcare experience, including more than 20 years providing leadership to information technology departments in global pharmaceutical companies and clinical research organizations.
CRA Names Quality Assurance VP
Research services provider Clinical Research Advantage (CRA) has added Joanne Mashburn as VP of quality assurance.
Ms. Mashburn is responsible for the overall planning and implementation of quality assurance initiatives within CRA’s 34 clinical research sites in Arizona, California, Colorado, Indiana, Iowa, Nebraska, and Nevada.
Ms. Mashburn has more than 12 years of experience in clinical research, most recently as the associate director of integrated site services for Quintiles. She holds an MSN from Grand Canyon University.
Emron Expands Staff
Andrea Burnett has joined Emron as a medical writer. Ms. Burdett spent more than five years at Klick Communications as a medical writer and editor. She holds an MPH from Emory University.
Emron also has hired Michael Sheffield as executive VP of sales and marketing. Most recently, Mr. Sheffield was director of business development with LeapFrog Rx. He has an MBA from the University of St. Thomas.
Emron is a managed markets agency specializing in market research, marketing communications, and sales training.
Former Publicis Groupe Executive Joins WebMD
WebMD Health Corp., an online provider of health information, has appointed David Marek executive VP, consumer services. Mr. Marek is responsible for WebMD’s leading consumer sites, including content, editorial, programming, product development, marketing, and other aspects of the user and advertiser experience.
Mr. Marek has more than 20 years of healthcare industry and agency experience, including more than a decade within Publicis Groupe, where he most recently served as worldwide business director.
Olson Research Appoints VP to Oversee R&D
Olson Research Group has appointed Paul Allen executive VP responsible for overseeing the company’s research and development efforts. Mr. Allen was previously president of Genactis. In other moves, Miina Rafinski has been promoted to director of client services, from manager of support services.
Sales Directors Added at Rx Edge
Rx Edge Pharmacy Networks has added two executive directors, sales, to its team.
Timothy Casatelli was previously director, business development, for Catalina Health, and holds an MBA from Saint Joseph’s University. Curt Meyer joins Rx Edge from Infomedics.
Mr. Casatelli and Mr. Meyer are responsible for supporting all elements of the sales process for Rx Edge retail pharmacy-based products and services, including Solutions at the Shelf, which is focused on patient acquisition; and HealthTrack, the company’s digital adherence program.
RxTrials Promotes Operating Chief
Adam Chasse has been promoted to chief operating officer at RxTrials, a network of clinical research sites and a consulting firm. Mr. Chasse’s duties include overseeing operational delivery within the site network and consulting divisions, as well as corporate strategy and planning.
Mr. Chasse joined RxTrials in 2011 as VP of corporate development. He holds a master of healthcare administration from the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill.
New President at QuantiaMD
QuantiaMD has named Mike Coyne president as the service company scales its physician community and leverages its unique engagement model to expand into new markets. Mr. Coyne joins QuantiaMD after serving as CEO for Verisk Health. He received an MBA from Fordham University and a J.D. from St. John’s University.
Modality Solutions Bolsters Engineering Expertise
Modality Solutions, a privately held company that delivers integrated cold-chain management solutions for highly regulated industries, has hired Shubhra Kochar as a consulting engineer. Ms. Kochar’s duties include helping the company deliver its integrated cold-chain management solutions utilizing quality engineering/logistics consulting, systems integration, and simulation laboratory services.
Symphony Health Expands Leadership Team
Nigel Pratt has joined Symphony Health Solutions as chief technology officer. Mr. Pratt has more than 27 years of software engineering experience in the United States and United Kingdom, including stints as senior VP of software development for market research firm Symphony IRI and VP of engineering at Symphony RPM.
Symphony Health Solutions provides multidimensional understanding of relevant information necessary to measure performance and inform strategies for optimal business decision-making.
Appature Adds Global Marketing VP
Appature, a software-as-a-service (SaaS) provider for life-sciences marketers, has appointed Jigish Avalani executive VP, global marketing and alliances. Mr. Avalani’s duties include bringing products to market and building effective alliances with leading life-sciences-focused agencies and IT consulting firms.
Before joining Appature, Mr. Avalani served in a variety of sales, marketing, and product management roles at Microsoft, most recently leading global market development for enterprise architecture services. He received a master’s degree in electrical engineering from Rutgers University.
Dr. Christine GARNETT
Former FDA Team Leader Joins Certara
Certara, a provider of scientific software and consulting services to improve productivity and decision-making from drug discovery through drug development, has appointed Christine Garnett, Pharm.D., principal scientist. Dr. Garnett leads development of next-generation cardiac safety modeling tools on the Phoenix software platform and also works closely with Pharsight’s global consulting services team on predictive modeling engagements that leverage early clinical study data to assess the cardiac proarrhythmic risk of new drug candidates.
Dr. Garnett was team leader in the Division of Pharmacometrics, Office of Clinical Pharmacology, at the U.S. Food and Drug Administration.
Sitrof Technologies Appoints Business Development VP
Sitrof Technologies, a provider of IT, consulting, and technology solutions for life-sciences companies, has named Jay Rothe VP of business development. Mr. Rothe was previously president of Vital Path, a GE company specializing in data and information migration and ECM solutions.